256 related articles for article (PubMed ID: 20460512)
1. Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.
Ostrander JH; McMahon CM; Lem S; Millon SR; Brown JQ; Seewaldt VL; Ramanujam N
Cancer Res; 2010 Jun; 70(11):4759-66. PubMed ID: 20460512
[TBL] [Abstract][Full Text] [Related]
2. The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells.
Ikeda H; Taira N; Hara F; Fujita T; Yamamoto H; Soh J; Toyooka S; Nogami T; Shien T; Doihara H; Miyoshi S
Breast Cancer Res; 2010; 12(3):R43. PubMed ID: 20579400
[TBL] [Abstract][Full Text] [Related]
3. Visualization of Breast Cancer Metabolism Using Multimodal Nonlinear Optical Microscopy of Cellular Lipids and Redox State.
Hou J; Williams J; Botvinick EL; Potma EO; Tromberg BJ
Cancer Res; 2018 May; 78(10):2503-2512. PubMed ID: 29535219
[TBL] [Abstract][Full Text] [Related]
4. Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-alpha and survivin.
Vanderlaag KE; Hudak S; Bald L; Fayadat-Dilman L; Sathe M; Grein J; Janatpour MJ
Breast Cancer Res; 2010; 12(3):R32. PubMed ID: 20525379
[TBL] [Abstract][Full Text] [Related]
5. High-throughput measurements of the optical redox ratio using a commercial microplate reader.
Cannon TM; Shah AT; Walsh AJ; Skala MC
J Biomed Opt; 2015 Jan; 20(1):010503. PubMed ID: 25634108
[TBL] [Abstract][Full Text] [Related]
6. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
7. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer.
Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K
Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258
[TBL] [Abstract][Full Text] [Related]
8. Potential Biomarker for Triple-Negative Breast Cancer Invasiveness by Optical Redox Imaging.
Feng M; Xu HN; Jiang J; Li LZ
Adv Exp Med Biol; 2021; 1269():247-251. PubMed ID: 33966225
[TBL] [Abstract][Full Text] [Related]
9. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
[TBL] [Abstract][Full Text] [Related]
10. Potential Indexing of the Invasiveness of Breast Cancer Cells by Mitochondrial Redox Ratios.
Sun N; Xu HN; Luo Q; Li LZ
Adv Exp Med Biol; 2016; 923():121-127. PubMed ID: 27526133
[TBL] [Abstract][Full Text] [Related]
11. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
[TBL] [Abstract][Full Text] [Related]
12. Estradiol regulates Tumor Necrosis Factor-α expression and secretion in Estrogen Receptor positive breast cancer cells.
To SQ; Cheung V; Lazarus KA; Knower KC; Clyne CD
Mol Cell Endocrinol; 2014 Aug; 394(1-2):21-8. PubMed ID: 25004254
[TBL] [Abstract][Full Text] [Related]
13. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
14. Expression and regulation of Cyr61 in human breast cancer cell lines.
Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
[TBL] [Abstract][Full Text] [Related]
15. ABCC11 expression is regulated by estrogen in MCF7 cells, correlated with estrogen receptor alpha expression in postmenopausal breast tumors and overexpressed in tamoxifen-resistant breast cancer cells.
Honorat M; Mesnier A; Vendrell J; Guitton J; Bieche I; Lidereau R; Kruh GD; Dumontet C; Cohen P; Payen L
Endocr Relat Cancer; 2008 Mar; 15(1):125-38. PubMed ID: 18310281
[TBL] [Abstract][Full Text] [Related]
16. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant.
Long X; Fan M; Nephew KP
Cancer Biol Ther; 2010 Mar; 9(5):389-96. PubMed ID: 20061804
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia reduces hormone responsiveness of human breast cancer cells.
Kurebayashi J; Otsuki T; Moriya T; Sonoo H
Jpn J Cancer Res; 2001 Oct; 92(10):1093-101. PubMed ID: 11676860
[TBL] [Abstract][Full Text] [Related]
19. Reversal of the estrogen receptor negative phenotype in breast cancer and restoration of antiestrogen response.
Bayliss J; Hilger A; Vishnu P; Diehl K; El-Ashry D
Clin Cancer Res; 2007 Dec; 13(23):7029-36. PubMed ID: 18056179
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
